ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Tripathy on Determining the Best HER2 Targeted Therapy

Debu Tripathy, MD
Published: Thursday, Aug 25, 2011

Debu Tripathy, MD, professor of medicine and co-leader of the Women’s Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, talks about deciding the best HER2 treatment to give a patients, he mentions that in the first-line setting the FDA indication is to receive trastuzumab. If there is a recurrence there are more choices, such as deciding between trastuzumab and lapatinib.

Tripathy uses the side effect profile and consultations with patients to decide which drug to use. Each drug has different implications. Despite its larger side effect profile lapatinib has the benefit of being administered orally, which may be important to the patient. These are all items that need to be considered when choosing the best treatment.
Debu Tripathy, MD, professor of medicine and co-leader of the Women’s Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, talks about deciding the best HER2 treatment to give a patients, he mentions that in the first-line setting the FDA indication is to receive trastuzumab. If there is a recurrence there are more choices, such as deciding between trastuzumab and lapatinib.

Tripathy uses the side effect profile and consultations with patients to decide which drug to use. Each drug has different implications. Despite its larger side effect profile lapatinib has the benefit of being administered orally, which may be important to the patient. These are all items that need to be considered when choosing the best treatment.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x